Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
In Edinburgh, pharmacy valuation is 80-110 % of revenue (90 % average), with a regulated gross margin of 26-32 %. New creation is extremely rare (transfer/merger only).
Dominant profile: touristique · etudiante · capitale
Edinburgh (Scotland, United Kingdom) has about 488K inhabitants and shows strong tourist footfall boosting seasonal spending and average ticket, and large student population (~15-25 % of residents) driving low-cost and late-night demand. For a pharmacy project, this means a high average ticket and a setup cost above national by 25 %.
Local purchasing power and lead density allow targeting the high end of the revenue range from year 2. Concretely, initial investment calibrated for Edinburgh ranges from 1M GBP to 4.4M GBP, and Year 1 target revenue sits between 1.7M GBP and 5.2M GBP — a range that already factors in the local coefficients of this city (+25% vs average on costs, +15% vs average on purchasing power).
Competitive density: high (dense supply, segmentation required).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 1.7M GBP → 5.2M GBP | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Edinburgh, United Kingdom (cost +25% vs average, income +15% vs average).
This page combines multiple data sources for a factual analysis calibrated on Edinburgh.
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.